Suppr超能文献

约旦患者队列中影响糖尿病性黄斑水肿抗血管内皮生长因子治疗依从性的因素

Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients.

作者信息

Abu-Yaghi Nakhleh E, Abed Alaa M, Khlaifat Dana F, Nawaiseh Mohammed B, Emoush Laith O, AlHajjaj Heba Z, Abojaradeh Ala M, Hattar Mariana N, Abusaleem Sura K, Sabbagh Hashem M, Abu Gharbieh Yazan A, Quaqazeh Sura A

机构信息

Department of Special Surgery, Ophthalmology Division, The University of Jordan, Amman, Jordan.

School of Medicine, The University of Jordan, Amman, Jordan.

出版信息

Clin Ophthalmol. 2020 Mar 24;14:921-929. doi: 10.2147/OPTH.S248661. eCollection 2020.

Abstract

PURPOSE

To determine compliance rates and characteristics and to investigate factors affecting patients' adherence to treatment with anti-vascular endothelial growth factors (anti-VEGFs) for diabetic macular edema (DME) in a cohort of Jordanian patients.

METHODS

A retrospective case series wherein the files of DME patients treated with anti-VEGFs were reviewed and analyzed for factors affecting treatment compliance was undertaken. Demographic, clinical and ocular characteristics were recorded. All patients were also interviewed by phone using a structured questionnaire. Univariate and multivariate analyses were performed to determine factors associated with compliance.

RESULTS

A total of 117 patients (65 males 52 females) were included in this study with a mean age of 62.93 years (±9.75). Approximately, 85% of patients were compliant to their treatment and follow-up plan during the first year of management. Subjective perception of visual improvement after receiving three loading doses was the only independent variable with a unique statistically significant contribution to compliance. All other studied factors in this group of patients were not significantly associated with patient compliance.

CONCLUSION

VEGF suppression via the intravitreal route to treat DME is a long-term process that requires caregiver dedication but also proper patient compliance. Addressing real-life barriers in those patients may help guide future strategies to improve the treatment experience, lower the financial burden and contribute to better outcomes. Patients' perceptions of possible treatment outcomes at the short term may influence their long-term commitment to therapy.

摘要

目的

在一组约旦患者中,确定糖尿病性黄斑水肿(DME)患者使用抗血管内皮生长因子(抗VEGF)治疗的依从率和特征,并调查影响患者坚持治疗的因素。

方法

进行一项回顾性病例系列研究,回顾并分析接受抗VEGF治疗的DME患者档案中影响治疗依从性的因素。记录人口统计学、临床和眼部特征。所有患者还通过电话使用结构化问卷进行访谈。进行单因素和多因素分析以确定与依从性相关的因素。

结果

本研究共纳入117例患者(65例男性,52例女性),平均年龄62.93岁(±9.75)。在治疗的第一年,约85%的患者遵守其治疗和随访计划。接受三次负荷剂量后视力改善的主观感受是唯一对依从性有独特统计学显著贡献的独立变量。该组患者中所有其他研究因素与患者依从性均无显著相关性。

结论

通过玻璃体腔内途径抑制VEGF治疗DME是一个长期过程,需要护理人员的奉献精神以及患者的适当依从性。解决这些患者在现实生活中的障碍可能有助于指导未来改善治疗体验、减轻经济负担并促成更好治疗结果的策略。患者对短期可能治疗结果的认知可能会影响他们对治疗的长期坚持。

相似文献

5
Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Curr Eye Res. 2021 Sep;46(9):1378-1386. doi: 10.1080/02713683.2021.1878540. Epub 2021 Jan 31.
7
Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Ophthalmology. 2019 Jul;126(7):1007-1015. doi: 10.1016/j.ophtha.2018.09.040. Epub 2018 Oct 4.
9
Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
Am J Ophthalmol. 2018 Nov;195:209-222. doi: 10.1016/j.ajo.2018.08.004. Epub 2018 Aug 9.
10
Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review.
Clin Ophthalmol. 2018 Oct 29;12:2189-2198. doi: 10.2147/OPTH.S170089. eCollection 2018.

引用本文的文献

2
Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema.
Int J Ophthalmol. 2025 Mar 18;18(3):454-461. doi: 10.18240/ijo.2025.03.12. eCollection 2025.
3
Factors Influencing Treatment Preference in Patients with Diabetic Macular Edema: A Study Using Conjoint Analysis.
Ophthalmol Ther. 2024 Nov;13(11):2887-2901. doi: 10.1007/s40123-024-01026-6. Epub 2024 Sep 17.
4
Factors Affecting Compliance and Visual Outcomes in Patients Receiving Intravitreal Bevacizumab Injections.
Cureus. 2024 Aug 13;16(8):e66760. doi: 10.7759/cureus.66760. eCollection 2024 Aug.
8
Impact of COVID-19-related lockdown on retinal disorders treated with intravitreal injections.
Oman J Ophthalmol. 2022 Jun 29;15(2):168-174. doi: 10.4103/ojo.ojo_74_21. eCollection 2022 May-Aug.
10
Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema.
Cells. 2021 Jul 3;10(7):1683. doi: 10.3390/cells10071683.

本文引用的文献

2
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting.
J Ophthalmol. 2018 Apr 18;2018:4610129. doi: 10.1155/2018/4610129. eCollection 2018.
3
Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients.
Clin Ophthalmol. 2017 Dec 20;12:13-20. doi: 10.2147/OPTH.S151611. eCollection 2018.
7
Fluocinolone acetonide for the treatment of diabetic macular edema.
Expert Opin Pharmacother. 2017 Oct;18(14):1507-1516. doi: 10.1080/14656566.2017.1363182. Epub 2017 Aug 9.
8
Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
Ophthalmologica. 2016;236(4):207-214. doi: 10.1159/000453006. Epub 2016 Nov 30.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验